A new drug for fibrodysplasia ossification progressive:palovarotene
Palovarotene is an orally available selective retinoic acid receptor(RAR)agonist developed by Ipsen Biophar-maceuticals Company of France for the treatment of children(female children over 8 years of age and male children over 10 years of age)and adults with fibrodysplasia ossification progressiva(FOP).On August 16,2023,the U.S.FDA approved Pal-ovarotene for marketing.In this paper,the pharmacological action,mechanism,pharmacokinetics,clinical efficacy,and safety of palovarotene were reviewed to provide some guidance for clinical rational drug use.
NETL
NSTL
万方数据
